Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES ...
SILVER SPRING, Md., Feb. 24, 2021 /PRNewswire/ — Today, the Tuberous Sclerosis Alliance (TS Alliance) and Nobelpharma America, LLC (NPA) announced an ongoing collaboration. As part of this partnership ...
Epidiolex is a pharmaceutical formulation of highly purified cannabidiol. The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Epidiolex® (cannabidiol; ...
DUBLIN--(BUSINESS WIRE)--The "Tuberous Sclerosis Complex - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Tuberous Sclerosis Complex Pipeline Insight, 2020 ...
He is fit and well with no epilepsy, mental illness, renal disease, or atopy. He has no risk factors of keratoconus such as steroid use or vernal conjunctivitis. There is no family history of tuberous ...
The complex process of human brain development plays an overlooked role in the manifestation of tuberous sclerosis, which leads to multiple noncancerous growths, previously thought to be solely due to ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options. A team led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback